KEYNOTE-224: Second-line pembrolizumab for advanced hepatocellular carcinoma

KEYNOTE-224: pembrolizumab monotherapy for previously untreated HCCПодробнее

KEYNOTE-224: Improving HCC Outcomes With PembrolizumabПодробнее

Dr. Finn on Studies of Pembrolizumab in Hepatocellular CarcinomaПодробнее

Two Options for Checkpoint Inhibition in HCCПодробнее

Molecular Targeted Therapies for Advanced HCCПодробнее

Dr. Zhu Discusses Findings of the KEYNOTE-224 in HCCПодробнее

KEYNOTE-240: pembrolizumab in advanced HCCПодробнее

KEYNOTE-224: Second-Line Pembrolizumab’s Value in HCCПодробнее

Emerging Second-Line Therapies in HCCПодробнее

Optimal Management of HCC: Integrating Novel Therapeutic Approaches Across the Continuum of CareПодробнее

Second-Line Therapy in Advanced HCCПодробнее

HCC: Optimizing Outcomes With New and Emerging Treatment ApproachesПодробнее

The HCC Treatment Algorithm: New and Emerging Monotherapy, Combination, and Multimodal ApproachesПодробнее

Approaching Second-Line Therapy for Advanced HCCПодробнее

Advanced hepatocellular carcinoma and personalised therapyПодробнее

Checkpoint inhibitors for the treatment of advanced hepatocellular carcinomaПодробнее

Richard S. Finn, MD, elaborates on promising developments in the second-line treatment of HCCПодробнее

Hepatocellular Carcinoma: A Guide to Integrating Emerging Therapies into Current Treatment ParadigmsПодробнее

Debate: Is there a standard second line therapy for HCC? - Regorafenib is a winnerПодробнее